Hypertension in the elderly

Cardiology Review

Volumn 23, Issue 9, 2006, Pages 24-34

  Gradman, Alan H ^a   Morsy, Mohamed ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; AMLODIPINE; AMLODIPINE BESYLATE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL FUMARATE; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CARVEDILOL; CHLORTALIDONE; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; EPLERENONE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; LOSARTAN POTASSIUM; METOPROLOL; METOPROLOL TARTRATE; MINOXIDIL; PERINDOPRIL; PROPRANOLOL; TERAZOSIN; TIMOLOL; TIMOLOL MALEATE; UNINDEXED DRUG; VALSARTAN;

ADD ON THERAPY; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIABETIC NEPHROPATHY; DIET; DRUG ANTAGONISM; DRUG POTENTIATION; ELDERLY CARE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; LIFESTYLE; LOW DRUG DOSE; MATURITY ONSET DIABETES MELLITUS; META ANALYSIS; ORTHOSTATIC HYPOTENSION; PERIPHERAL EDEMA; REVIEW; STROKE; SYSTEMATIC REVIEW; SYSTOLIC HYPERTENSION; TREATMENT INDICATION;

EID: 33749175832     PISSN: 10926607     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged men and women: the Framingham Heart Study. JAMA. 2002;287(8):1003-1011.
2. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003;290(22):199-206.
3. Burt VL, Whelton P, Roccella EJ et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995;25(3):305-313.
4. Lewington S, Clarke R, Qizilbash N, et al. for the Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360[9349]:1903-1913.
5. Izzo JL Jr, Levy D, Black HR. Importance of systolic blood pressure in older Americans. Hypertension. 2000;35:1021-1024.
6. Chobanian AV, Bakris GL, Black HR, et al. and the National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206-1252.
7. Turbull F, Neal B, Algert C, et al. Effects of different blood pressure lowering regimens on major cardiovascular events: results of prospectively designed overviews of randomized trials. Blood Pressure Lowering Treatment Trialists Collaboration. Lancet. 2003;362:1527-1535.
8. Franklin SS, Khan SA, Wong ND, Larson MG, Levy D. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham heart study. Circulation. 1999;100(4):354-360.
9. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991;265(24):3255-3264.
10. Smulyan S, Safar ME. The diastolic blood pressure in systolic hypertension. Ann Intern Med. 2000;132(3):233-237.
11. Simon G. Pathogenesis of structural vascular changes in hypertension. J Hypertens. 2004;22(1):3-10.
12. Cutler JA. Randomized trials of sodium reduction: an overview. Am J Clin Nutr. 1997;65(2 suppl):643S-651S.
13. Whelton PK, Appel LJ, Espeland MA, et al. Sodium reduction and weight loss in the treatment of hypertension in the older persons: a randomized controlled trial of non-pharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. JAMA. 1998;279(11):839-846.
14. Hansson L, Lindholm LH, Ekbom T, et al. Randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999; 354(9192):1751-1756.
15. SHEP Cooperative Research Group. Prevention of stroke by anrihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265(24):3255-3264.
16. MRC Working Party. Medical Research Council trial of treatment of hyertension in older adults. Principal results. BMJ. 1992;304:405-412.
17. Messerli FH, Grossman E, Goldburt U. Are beta-blockers efficacious as first line therapy for hypertension in the elderly: a systematic review. JAMA. 1998;279(23):1903-1907.
18. Staessen JA, Fagard R, Thijs L, et al. Randomized double-blind comparison of placebo and active treatment for old patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350(9080):757-764.
19. Liu L, Wang JG, Gong L, et al. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens. 1998;16(12 pt 1):1823-1829.
20. Staessen JA, Gasowski J, Want JG, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet. 2000;355(9207):865-872.
21. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981-2997.
22. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363(9426):2022-2031.
23. Dahlof B, Sever PS, Poutler NR, et al, for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895-906.
24. Hanes DS, Weir MR. The beta blockers: are they as protective in hypertension as in other cardiovascular conditions? J Clin Hypertens (Greenwich). 2001;3(4):236-243.
25. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327(10):669-677.
26. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893-1906.
27. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309-1321.
28. Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000; 342:145-153.
29. Fox KM, for the European trial on reduction of cardiac events with perindopril in patients with stable coronary artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease. Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362(9386):782-788.
30. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001; 358(9287):1033-1041.
31. Dahlof B, Devereux RB, Kjeldsen SE, et al, for the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For End point reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995-1003.
32. Lewis EJ, Hunsicker LG, Clarke WR, et al, for the Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
33. Brenner BM, Cooper ME, de Zeeuw D, et al, for the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
34. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group. The effect of angiotensin converting- enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456-1462.
35. Bakris GL, Williams M, Dworkin L, et al, for the National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Preserving renal function in adults with hypertension and diabetes. A consensus approach. Am J Kidney Dis. 2000;36:646-661.
36. Zuschke CA. Pseudohypertension. Lancet. 2001;88(12):1185-1190.